StockData
Ironwood Pharmaceuticals Inc logo

Ironwood Pharmaceuticals Inc (IRWD) stock

IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3063% below fair value
$4.87+0.02 (+0.41%)

Close on Nov 17, 2026Market cap $804.72MP/E 6.3Yield –

Ironwood Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Ironwood Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $389.32M, up 26.2% year over year. For fiscal 2025 it was $296.15M, down 15.7% from the year before. Over ten years it grew 7.1% a year on average. The highest annual figure on record is $442.74M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$296.15M-15.7%
FY2024Dec 31, 2024$351.41M-20.6%
FY2023Dec 31, 2023$442.74M+7.8%
FY2022Dec 31, 2022$410.60M-0.8%
FY2021Dec 31, 2021$413.75M+6.2%
FY2020Dec 31, 2020$389.52M-9.1%
FY2019Dec 31, 2019$428.41M+23.6%
FY2018Dec 31, 2018$346.64M+16.2%
FY2017Dec 31, 2017$298.28M+8.9%
FY2016Dec 31, 2016$273.96M+83.2%
FY2015Dec 31, 2015$149.56M+95.7%
FY2014Dec 31, 2014$76.44M+234.1%
FY2013Dec 31, 2013$22.88M-84.8%
FY2012Dec 31, 2012$150.25M+128.1%
FY2011Dec 31, 2011$65.87M+50.2%
FY2010Dec 31, 2010$43.86M+27.8%
FY2009Dec 31, 2009$34.32M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$113.04M+32.6%
Q1 FY2026Mar 31, 2026$106.51M+158.9%
Q4 FY2025Dec 31, 2025$47.71M-47.3%
Q3 FY2025Sep 30, 2025$122.06M+33.3%
Q2 FY2025Jun 30, 2025$85.24M-9.7%
Q1 FY2025Mar 31, 2025$41.14M-45.1%
Q4 FY2024Dec 31, 2024$90.55M-23.0%
Q3 FY2024Sep 30, 2024$91.59M-19.5%
Q2 FY2024Jun 30, 2024$94.40M-12.1%
Q1 FY2024Mar 31, 2024$74.88M-28.0%
Q4 FY2023Dec 31, 2023$117.55M+9.7%
Q3 FY2023Sep 30, 2023$113.74M+4.7%
Q2 FY2023Jun 30, 2023$107.38M+10.4%
Q1 FY2023Mar 31, 2023$104.06M+6.7%
Q4 FY2022Dec 31, 2022$107.20M-8.5%
Q3 FY2022Sep 30, 2022$108.64M+4.7%
Q2 FY2022Jun 30, 2022$97.23M-6.5%
Q1 FY2022Mar 31, 2022$97.53M+9.8%
Q4 FY2021Dec 31, 2021$117.13M+0.4%
Q3 FY2021Sep 30, 2021$103.75M+0.3%
Q2 FY2021Jun 30, 2021$104.03M+16.3%
Q1 FY2021Mar 31, 2021$88.85M+11.1%
Q4 FY2020Dec 31, 2020$116.68M-7.6%
Q3 FY2020Sep 30, 2020$103.47M-21.1%
Q2 FY2020Jun 30, 2020$89.43M-12.5%
Q1 FY2020Mar 31, 2020$79.94M+16.3%
Q4 FY2019Dec 31, 2019$126.30M-3.4%
Q3 FY2019Sep 30, 2019$131.17M+99.7%
Q2 FY2019Jun 30, 2019$102.22M+26.0%
Q1 FY2019Mar 31, 2019$68.73M-0.6%
Q4 FY2018Dec 31, 2018$130.69M+38.7%
Q3 FY2018Sep 30, 2018$65.69M-24.3%
Q2 FY2018Jun 30, 2018$81.11M+24.6%
Q1 FY2018Mar 31, 2018$69.16M+32.6%
Q4 FY2017Dec 31, 2017$94.21M+7.7%
Q3 FY2017Sep 30, 2017$86.83M+31.3%
Q2 FY2017Jun 30, 2017$65.08M–
Q1 FY2017Mar 31, 2017$52.17M–
Q4 FY2016Dec 31, 2016$87.46M–
Q3 FY2016Sep 30, 2016$66.11M–

More Ironwood Pharmaceuticals figures

See a number that looks wrong?